Clinical Trial Update: A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study [Phase 3]

View source ↗

Summary

This Phase 3 multicenter, open-label study evaluated the ease of use of the RebiSmart autoinjector in multiple sclerosis patients; results were posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Rebif (interferon beta-1a)

Snippet

Sponsor: EMD Serono | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2010-12-22